Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a new study shows.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Li, president of Merck Research Laboratories, stressing that "HRS-5346, an investigational oral small molecule inhibitor of Lp(a) formation, is an important addition that expands and complements our ...

Mark T. Esser, a pharmaceutical researcher and executive, brings scientific expertise and leadership experience to his new ...

Listen to this article Mark T. Esser, vice president for vaccines and immune therapies at pharmaceutical giant AstraZeneca, will be the inaugural chief scientific officer and leader of the Paul and ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Winrevair (sotatercept-csrk) significantly reduced the risk of death, lung transplant, or hospitalization in people with PAH.

Nvidia NVDA.O will open a quantum computing research lab in Boston, where it plans to collaborate with scientists from Harvard University and the Massachusetts Institute of Technology ...

Li, president of Merck Research Laboratories. “HRS-5346, an investigational oral small molecule inhibitor of Lp(a) formation, is an important addition that expands and complements our cardio ...

Dr. Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, also highlighted the innovative approach of the subcutaneous ...